In short
Section 3(d) says a new form of a known substance is not patentable unless it shows significantly enhanced efficacy. When the examiner raises it, argument does not answer it: comparative laboratory data does. You need a properly controlled experiment comparing your new form against the known substance on a relevant efficacy endpoint, reported so an examiner can read it, and delivered inside the Rule 24B response window. Manna Biotech generates that data; your registered patent agent files it.
What Section 3(d) actually says, in plain words
Section 3(d) of the Patents Act 1970 excludes from patentability the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance. Salts, esters, ethers, polymorphs, metabolites, pure forms, particle sizes, isomers, mixtures of isomers, complexes, combinations and derivatives are all treated as the same substance unless they differ significantly in properties with regard to efficacy.
The practical meaning: if your invention is a new version of something already known, the Indian Patent Office will assume it is the same thing until you prove, with data, that it works meaningfully better. The burden is on the applicant.
Why the examiner will not accept your argument alone
Applicants often respond to a 3(d) objection with a well-written legal explanation of why the new form is different. Examiners routinely reject this, because the section turns on a factual question (is efficacy enhanced?) and facts need evidence. The Supreme Court in the Novartis matter made clear that efficacy means therapeutic efficacy and that it must be shown, not asserted.
So the response your patent agent files needs an experimental annexure: methods, materials, controls, raw results, statistics and a conclusion. Without that, the objection usually stands.
What a persuasive comparative efficacy study looks like
- A defined comparator: the known substance, tested side by side under identical conditions, not a literature value.
- A relevant endpoint: one that actually reflects efficacy for the claimed use, not a convenient surrogate.
- Adequate replication: enough repeats that the difference is statistically meaningful, not a single run.
- Controls that make the result interpretable: vehicle, positive control, and the known substance itself.
- A report written for an examiner: clear methods, tabulated data, a plain statement of what was and was not shown.
Which assays generate 3(d) data for life-science inventions
| Type of invention | Efficacy endpoint that fits | Assay that produces the data |
|---|---|---|
| Antimicrobial formulation, herbal or synthetic | Potency against defined strains | MIC and MBC by broth microdilution per CLSI; zone of inhibition |
| Antifungal or antibiofilm agent | Growth or biofilm inhibition | Broth microdilution; crystal-violet biofilm assay |
| Probiotic or microbial consortium | Strain identity, viability, activity | WGS or 16S identification; biochemical characterisation; activity assays |
| Nutraceutical or herbal active | Antioxidant, anti-inflammatory or bioactivity readouts | In vitro bioactivity panels; comparative dose response |
| Formulation with claimed mechanism | Target gene or protein expression | RT-qPCR; Western blot; transcriptomics |
The timeline trap: Rule 24B
A First Examination Report must be answered within six months of issue, extendable by three. Some comparative studies, anything involving cell culture, sequencing or repeated microbial assays, genuinely take weeks. If you begin the experiment late, the data will not exist by the deadline and the application can be deemed abandoned.
Tell your data provider the response deadline in the first message. A competent laboratory will say plainly whether the study can be completed and reported in time, and will decline rather than start something that cannot land.
Who does what: the science and the law are different jobs
Under Section 129 of the Patents Act, only a registered patent agent may prepare specifications, file, or prosecute a patent application on your behalf. That includes writing the response to the examiner. What the agent needs from you is evidence they can rely on, and evidence comes from a bench, not a law office.
Manna Biotech provides the scientific and technical layer: study design, laboratory execution and an examiner-ready technical report. Your registered patent agent files it and argues the law. Both roles are essential; neither replaces the other.
Frequently asked questions
Can data generated after filing be used to answer a 3(d) objection?+
Yes. Comparative efficacy data is routinely generated during prosecution, in response to the objection, and submitted with the reply. The invention must have been disclosed at filing; the supporting evidence can come later.
Does the data have to come from an NABL-accredited laboratory?+
No. There is no accreditation requirement for research data submitted to the Patent Office. What matters is that the study is properly designed, controlled, documented and reported. Manna Biotech is not NABL/ISO 17025 accredited and states this openly; where an accredited report is separately required for a regulatory purpose, that is arranged through partner laboratories.
Will you guarantee the data overcomes the objection?+
No, and no honest provider will. What is guaranteed is a properly designed comparison, competently run and honestly reported. Whether it persuades the examiner is the Patent Office's decision, and whether it is argued well is your patent agent's job.
How quickly can Manna Biotech produce 3(d) data?+
It depends on the assay. Antimicrobial efficacy work can move quickly; sequencing and transcriptomics take longer. Share the objection and the deadline first and you will get an honest timeline before you commit.